Oncology in Clinical Practice (@OCPJournal) header
Oncology in Clinical Practice (@OCPJournal) profile picture

Oncology in Clinical Practice (OCP) – Peer-reviewed Open Access journal on neoplastic diseases. Publishes research, reviews, case studies, and more.

ul. Roentgena 5, Warszawa
Joined September 2024
Photo by Oncology in Clinical Practice (@OCPJournal)Photo by Oncology in Clinical Practice (@OCPJournal)Photo by Oncology in Clinical Practice (@OCPJournal)Photo by Oncology in Clinical Practice (@OCPJournal)Photo by Oncology in Clinical Practice (@OCPJournal)Photo by Oncology in Clinical Practice (@OCPJournal)Photo by Oncology in Clinical Practice (@OCPJournal)Photo by Oncology in Clinical Practice (@OCPJournal)Photo by Oncology in Clinical Practice (@OCPJournal)Photo by Oncology in Clinical Practice (@OCPJournal)
What should every oncology team know about antineoplastic drug extravasation? In their latest expert review, Maryna Rubach and colleagues provide a practical, drug-by-drug guide for clinical oncologists. 📖doi.org/10.5603/ocp.114884 #ClinicalOncology #PatientSafety
1
1
1
73
60% of GI cancer patients reported eating less red meat during chemotherapy. Could taste changes play a role? Explore the findings on dysgeusia, nutrition and QoL. Authors: Julianna Dąbrowa, Joanna Królikowska, Piotr Walecki, Paweł M. Potocki doi.org/10.5603/ocp.112896
1
41
New review: emerging targets in aggressive TNBC, including B7-H4, HER3, LIV-1 and ATR/WEE1, may support biomarker-guided therapy. Author: Dilpreet Singh DOI: doi.org/10.5603/ocp.112474 #TNBC #BreastCancer
40
New EU breast cancer approvals are reshaping biomarker testing, ADC sequencing and first-line TNBC care. Authors: Katarzyna Pogoda, Barbara Radecka doi.org/10.5603/ocp.114860 #BreastCancer #Oncology #ClinicalPractice
26
Lower hemoglobin and lower lymphocyte-to-monocyte ratio (LMR) were independently associated with shorter overall survival in patients with metastatic colorectal cancer treated with targeted biological agents. Their predictive value remains uncertain. doi.org/10.5603/ocp.114424
1
1
47
Adult colonic intussusception can signal malignancy. A 20-year-old woman was found to have mucinous ascending-colon adenocarcinoma and FAP. Authors: Julia Ciesielska, Szymon Niemiec, Andrzej Guzik, Joanna Kobak. doi.org/10.5603/ocp.112828 #ColorectalCancer
117
BRAF/MEK therapy led to complete regression of a right atrial melanoma metastasis, highlighting the potential role of targeted therapy and serial echocardiographic monitoring in cardiac involvement. doi.org/10.5603/ocp.112654 #Melanoma #CardiacMetastasis #BRAFV600E #Oncology
1
29
Fatal pulmonary hypertension after 17 months of alectinib in a 39-year-old woman with ALK+ NSCLC. The case suggests a rare ALK-inhibitor vascular toxicity, though causality was not confirmed. doi.org/10.5603/ocp.113041 #NSCLC #Alectinib
44
Case report: squamous cell lung cancer in a 25-year-old man after short-term asbestos exposure. Authors: Tobiasz Wróblewski, Katarzyna Ostrowska, Paulina Wesołowska, Filip K. Gajewski, Beata Gryglicka, Karolina Dubiel-Kosikowska, Paweł Krawczyk doi.org/10.5603/ocp.113154 #NSCLC
53
A narrative review explores ICI efficacy in rare oncogene-driven NSCLC. BRAF-mutated tumors appear most responsive, while targeted therapies remain preferred for most subgroups. Authors: Paulina Kalman, Magdalena Knetki-Wróblewska doi.org/10.5603/ocp.113505 #NSCLC #Immunotherapy
22
A rare case of dynamic HER2 discordance in breast cancer shows how receptor status may change over time and after treatment, highlighting the value of repeat biomarker reassessment in recurrent or residual disease. doi.org/10.5603/ocp.111460 #BreastCancer #HER2 #Oncology
22
Cancer cachexia requires multimodal care. This review highlights early, individualized management combining nutrition, exercise, pharmacotherapy and emerging targeted therapies. Authors: Zuzanna Kościów, Klaudia Gutowska. doi.org/10.5603/ocp.113525 #Cachexia #Oncology
47
Poland: #ProstateCancer incidence rose in 2013–2023; age-standardized mortality stayed broadly stable but remains above the EU average. Authors: Michał Seweryn, Paweł M. Potocki, Janusz Ligeza, Anna B. Łuc-Seweryn, Paweł Koczkodaj doi.org/10.5603/ocp.113452 #Oncology
71
New review of nectins and nectin-like molecules in melanoma, lung cancer and RCC. Nectin-4 and CD155/TIGIT are highlighted as key targets for ADCs, checkpoint blockade and oncolytic virotherapy. journals.viamedica.pl/oncolo… #Nectins #Nectin4 #TIGIT #Melanoma #LungCancer #Oncology
1
37
Interim UROCAPOL data suggest split-dose cisplatin may be underused in metastatic urothelial carcinoma. Avelumab ORR was 66.7% after split-dose GC vs 12.5% after GK. journals.viamedica.pl/oncolo… #UrothelialCancer #Avelumab
37
#Atezolizumab may be a first-line option for older patients with advanced #NSCLC who cannot receive platinum doublets. Full article: journals.viamedica.pl/oncolo…
15
Can DDR1 help overcome resistance to ICI therapy in CRC? This review highlights its role in the tumor microenvironment and potential as a therapeutic target in pMMR/MSS disease. Authors: Jiali Zhang, Huixiu Liu, Chiyu Zhang, Xiong Bin journals.viamedica.pl/oncolo…
28
KIF5B-ALK–positive lung adenocarcinoma showed a partial response to crizotinib, underscoring the value of broad molecular profiling for targeted therapy. journals.viamedica.pl/oncolo… #LungCancer #NSCLC #Crizotinib
28
Antibody–drug conjugates are transforming breast cancer treatment. This systematic review highlights efficacy across subtypes while emphasizing key challenges, including optimal sequencing and toxicity management. journals.viamedica.pl/oncolo… #BreastCancer #Oncology
42
ECOG performance status is a strong independent prognostic factor for survival in mNSCLC patients treated with nivolumab after platinum-based chemo. journals.viamedica.pl/oncolo… #NSCLC #Nivolumab
1
41